Andrew Huberman· PhD
It's GBRS? - Yeah. - Is your program. I'm going to sign up for this. This is not a promotional. I'm just going to do it. I'm going to pay full price. I'm going to insist on paying full price like everyone else.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
It's GBRS? - Yeah. - Is your program. I'm going to sign up for this. This is not a promotional. I'm just going to do it. I'm going to pay full price. I'm going to insist on paying full price like everyone else.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.